JANUARY 22, 2019
Kevin Kunzmann
New study results show that, despite recent international clinical analysis, direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is not associated with a greater recurrence of liver cancer in patients who have suffered from both conditions.
According to research from the University of Texas Southwestern Medical Center, rates of cancer aggressiveness and recurrence in DAA-treated patients with hepatitis C was no different from those not given antiviral therapy. The findings come as a benefit to patients and physicians alike; DAAs have been evidenced to provide a near-perfect rate of hepatitis C eradication in patients, with virus life cycle-targeting mechanism and proven tolerability.
Read more:
Liver Cancer Recurrence Not Linked to Hepatitis Treatment
Kristin Jenkins
January 24, 2019
The study was published online January 18 in Gastroenterology.
"Our results suggest use of direct-acting antivirals is safe and likely beneficial in hepatitis C–infected patients with a history of hepatocellular carcinoma," Singal told Medscape Medical News.
"We found no significant difference in the proportion of patients with recurrence or the aggressiveness of the recurrence between DAA-treated and untreated patients. Therefore, patients with a history of HCC who achieve complete response to cancer treatment should be referred for consideration of hepatitis C therapy," he said.
Read more:
*free registration may be required
Elsewhere
8 gastrointestinal, liver cancer stories you may have missed
January 24, 2019
Recently published studies have demonstrated new developments in the testing, diagnosis and treatment of gastrointestinal and liver cancers. In case you missed it, the…
Elsewhere
8 gastrointestinal, liver cancer stories you may have missed
January 24, 2019
Recently published studies have demonstrated new developments in the testing, diagnosis and treatment of gastrointestinal and liver cancers. In case you missed it, the…
No comments:
Post a Comment